Cargando…

Integrin Targeted Therapeutics

Integrins are heterodimeric, transmembrane receptors that function as mechanosensors, adhesion molecules and signal transduction platforms in a multitude of biological processes. As such, integrins are central to the etiology and pathology of many disease states. Therefore, pharmacological inhibitio...

Descripción completa

Detalles Bibliográficos
Autores principales: Millard, Melissa, Odde, Srinivas, Neamati, Nouri
Formato: Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086618/
https://www.ncbi.nlm.nih.gov/pubmed/21547158
_version_ 1782202708356235264
author Millard, Melissa
Odde, Srinivas
Neamati, Nouri
author_facet Millard, Melissa
Odde, Srinivas
Neamati, Nouri
author_sort Millard, Melissa
collection PubMed
description Integrins are heterodimeric, transmembrane receptors that function as mechanosensors, adhesion molecules and signal transduction platforms in a multitude of biological processes. As such, integrins are central to the etiology and pathology of many disease states. Therefore, pharmacological inhibition of integrins is of great interest for the treatment and prevention of disease. In the last two decades several integrin-targeted drugs have made their way into clinical use, many others are in clinical trials and still more are showing promise as they advance through preclinical development. Herein, this review examines and evaluates the various drugs and compounds targeting integrins and the disease states in which they are implicated.
format Text
id pubmed-3086618
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-30866182011-05-05 Integrin Targeted Therapeutics Millard, Melissa Odde, Srinivas Neamati, Nouri Theranostics Review Integrins are heterodimeric, transmembrane receptors that function as mechanosensors, adhesion molecules and signal transduction platforms in a multitude of biological processes. As such, integrins are central to the etiology and pathology of many disease states. Therefore, pharmacological inhibition of integrins is of great interest for the treatment and prevention of disease. In the last two decades several integrin-targeted drugs have made their way into clinical use, many others are in clinical trials and still more are showing promise as they advance through preclinical development. Herein, this review examines and evaluates the various drugs and compounds targeting integrins and the disease states in which they are implicated. Ivyspring International Publisher 2011-02-17 /pmc/articles/PMC3086618/ /pubmed/21547158 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Review
Millard, Melissa
Odde, Srinivas
Neamati, Nouri
Integrin Targeted Therapeutics
title Integrin Targeted Therapeutics
title_full Integrin Targeted Therapeutics
title_fullStr Integrin Targeted Therapeutics
title_full_unstemmed Integrin Targeted Therapeutics
title_short Integrin Targeted Therapeutics
title_sort integrin targeted therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086618/
https://www.ncbi.nlm.nih.gov/pubmed/21547158
work_keys_str_mv AT millardmelissa integrintargetedtherapeutics
AT oddesrinivas integrintargetedtherapeutics
AT neamatinouri integrintargetedtherapeutics